What do you consider the biggest challenge that the pharma/
biopharma industry currently faces?
Publication: Pharma's AlmanacPublished: June 24, 2022
Raj Indupuri, Chief Executive Officer, eClinical Solutions
The reliance on manual and siloed processes across all areas of drug development continues to hold the life sciences industry back. We have seen remarkable progress over the last two years in accelerating digital transformation in clinical development, but there remain significant opportunities to take the volumes of new data streams available in trials and turn them into insights and evidence about new therapies exponentially faster. The process of clinical development continues to be too slow and too costly to allow the industry and patients to fully benefit from the coming wave of immunotherapies that have the opportunity to transform human health. Adopting new technologies, digital trial models, and analytics and AI at scale to keep up with the scientific breakthroughs that are coming remains our biggest challenge.